BioSpace News Archive

Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2018, ended March 31, 2018

TESARO, Inc. will announce first-quarter 2018 financial results onThursday, May 3, 2018, after the close of the U.S. financial markets.

Metabolon, Inc. announced that the U.S. Department of Veterans Affairs (VA) has been contracted through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).

Pharmaleads will present at BioTrinity 2018 in London on Tuesday, April 24th at 3.35pm.

Senomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients and natural high intensity sweeteners, will issue its financial results on Thursday, April 26, 2018 at 4:05 p.m. Eastern time (1:05 p.m. Pacific time) for the first quarter ended March 31, 2018.

Sodexo Canada and its public relations agency, Xposure PR, have been honored with a 2018 Gold Quill Award of Merit in Media Relations from the International Association of Business Communicators (IABC).

Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company’s supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants

More than 20 per cent of patients with outpatient urinary tract infections (UTIs) receive an antibiotic to which the responsible pathogen is not susceptible

The biopharmaceutical company MOLOGEN AG announced today that the collaboration with ONCOLOGIE, agreed on in February 2018, is making good progress.

- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM - Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms